PI3K Inhibitor Delays Chemotherapy Start Free

Inavolisib (Itovebi; Genentech) boosted survival in patients with HR-positive, HER2-negative advanced breast cancer and extended the time they could wait before starting chemotherapy. In the phase III INAVO120 trial, median overall survival was 34 months for the 161 patients who received inavolisib, a PI3K inhibitor, with the CDK4/6 inhibitor palbociclib (Ibrance; Pfizer) and the estrogen blocker fulvestrant, compared with 27 months for those who received a placebo instead of inavolisib. The median time until patients needed to start chemotherapy was 35.6 months in the inavolisib group compared with 12.6 months in the placebo group. The results were presented during a press conference in advance of the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, where they will be presented more formally.